Coccidioidomycosis Overview

Save information for later
Sign Up

Learn About Coccidioidomycosis

What is the definition of Coccidioidomycosis?
Coccidiomycosis, also known as valley fever, is a fungal infection caused by the fungus, Coccidioides, that lives in the soil in the southwestern United States (Arizona, Utah, New Mexico, California (San Joaquin Valley), Texas, and south-central Washington and parts of Mexico and Central and South America. Coccidiomycosis is contracted by breathing in the fungal spores from the air, usually from dust caused by farming, construction, and wind. Once inhaled, the spores continue to reproduce in the lungs. Rarely, the fungal spores may enter the body through a cut or wound, causing a skin infection.
What are the symptoms of Coccidioidomycosis?
While many individuals with coccidiomycosis do not experience any symptoms, others may have symptoms for weeks or months. Symptoms of acute coccidiomycosis usually appear between 1 and 3 weeks after breathing in the fungal spores and may include fatigue, fever, chills, night sweats, shortness of breath, cough, headache, muscle aches, joint pain, and rash on the upper body or legs. Around 5 to 10% of individuals with coccidiomycosis will develop long-term or serious lung complications (chronic pneumonia), while about 1% will develop an infection of the central nervous system, such as the brain or spinal cord, or the skin, bones, or joints (disseminated coccidiomycosis).
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Coccidioidomycosis?
Most mild cases of coccidiomycosis do not require treatment and will resolve within a few months with rest, adequate fluid intake, and supportive care. Individuals with severe coccidiomycosis may be treated with antifungal medications, such as fluconazole (Diflucan), itraconazole (Sporanoz, Onmel, Tosura), amphotericin B (Albecet, Ambisome), voriconazole (Vfend), posaconazole (Noxafil), and isavuconazonium sulfate (Cresemba).
Who are the top Coccidioidomycosis Local Doctors?
Elite in Coccidioidomycosis
Dr. John N. Galgiani
Infectious Disease
Elite in Coccidioidomycosis
Dr. John N. Galgiani
Infectious Disease

Banner-University Medical Group

3838 N Campbell Ave, 
Tucson, AZ 
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Galgiani is an Infectious Disease provider in Tucson, Arizona. Dr. Galgiani and is rated as an Elite provider by MediFind in the treatment of Coccidioidomycosis. His top areas of expertise are Coccidioidomycosis, Pneumonia, Meningitis, and Blastomycosis. Dr. Galgiani is currently accepting new patients.

Elite in Coccidioidomycosis
Dr. Janis E. Blair
Infectious Disease
Elite in Coccidioidomycosis
Dr. Janis E. Blair
Infectious Disease

Mayo Clinic Arizona

5777 E Mayo Blvd, Mayo Clinic Hospital, 
Phoenix, AZ 
800-603-0558
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Janis Blair is an Infectious Disease provider in Phoenix, Arizona. Dr. Blair and is rated as an Elite provider by MediFind in the treatment of Coccidioidomycosis. Her top areas of expertise are Coccidioidomycosis, Meningitis, Pneumonia, and COVID-19. Dr. Blair is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Coccidioidomycosis
Dr. Neil M. Ampel
Infectious Disease
Elite in Coccidioidomycosis
Dr. Neil M. Ampel
Infectious Disease

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
480-301-8000
Languages Spoken:
English

Neil Ampel is an Infectious Disease provider in Scottsdale, Arizona. Dr. Ampel and is rated as an Elite provider by MediFind in the treatment of Coccidioidomycosis. His top areas of expertise are Coccidioidomycosis, Nontuberculous Mycobacterial Lung Disease, Meningitis, and Pneumonia.

View All Doctors
What are the latest Coccidioidomycosis Clinical Trials?
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety Tolerability and Pharmacokinetics of IDB-011 (IDB-774+IDB-898) in Healthy Adults
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety Tolerability and Pharmacokinetics of IDB-011 (IDB-774+IDB-898) in Healthy Adults
Enrollment Status: Recruiting
Publish Date: April 13, 2025
Intervention Type: Other, Drug
Study Phase: Phase 1

Summary: Phase 1 randomized, double-blind, placebo-controlled trial to evaluate safety, tolerability, pharmacokinetics (PK) and immunogenicity of IDB-011 following intramuscular (IM )administration of single ascending doses to healthy adult participants.

Match to trials
Find the right clinical trials for you in under a minute
Get started
The Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis
The Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis
Enrollment Status: Recruiting
Publish Date: March 30, 2025

Background: - Coccidioidomycosis is caused by a fungus that grows in the southwest United States and parts of Mexico and South America. This disease is caused by breathing dust containing the fungus. It can lead to serious lung and breathing problems. Rarely, the fungus can infect other body parts. This is called disseminated coccidioidomycosis (DCM). If the fungus stays in the lungs for more than 6 months, i...

View All Clinical Trials